These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17179928)

  • 1. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners.
    Hanafusa T; Imagawa A
    Nat Clin Pract Endocrinol Metab; 2007 Jan; 3(1):36-45; quiz 2p following 69. PubMed ID: 17179928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulminant type 1 diabetes mellitus in a GDM pregnancy: early recognition is vital for maternal and fetal outcomes.
    Choy KHA; Wong T; Cao RHM; Flack JR
    Endocrinol Diabetes Metab Case Rep; 2022 Jul; 2022():. PubMed ID: 35899692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulminant Type 1 Diabetes-East and West.
    Imagawa A; Hanafusa T
    J Clin Endocrinol Metab; 2023 Nov; 108(12):e1473-e1478. PubMed ID: 37309685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulminant type 1 diabetes: nationwide effort to elucidate genetics, etiology, and pathogenesis since 2000.
    Ikegami H; Imagawa A; Shimada A
    Diabetol Int; 2020 Oct; 11(4):342-343. PubMed ID: 33088641
    [No Abstract]   [Full Text] [Related]  

  • 5. Fulminant type 1 diabetes mellitus: a new class of type 1 diabetes.
    Shibasaki S; Imagawa A; Hanafusa T
    Adv Exp Med Biol; 2012; 771():20-3. PubMed ID: 23393667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fulminant type 1 diabetes mellitus].
    Imagawa A; Hanafusa T
    Rinsho Byori; 2010 Mar; 58(3):216-24. PubMed ID: 20408439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent findings on fulminant type 1 diabetes.
    Liu L; Zeng L; Sang D; Lu Z; Shen J
    Diabetes Metab Res Rev; 2018 Jan; 34(1):. PubMed ID: 28817230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulminant type 1 diabetes: recent research progress and future prospects.
    Imagawa A; Tachibana M
    Diabetol Int; 2020 Oct; 11(4):336-341. PubMed ID: 33088640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulminant type 1 diabetes: 20 years of discovery and development.
    Hanafusa T
    Diabetol Int; 2020 Oct; 11(4):310-314. PubMed ID: 33088636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
    Kyriacou A; Melson E; Chen W; Kempegowda P
    Clin Med (Lond); 2020 Jul; 20(4):417-423. PubMed ID: 32675150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
    de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
    Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy.
    Baden MY; Imagawa A; Abiru N; Awata T; Ikegami H; Uchigata Y; Oikawa Y; Osawa H; Kajio H; Kawasaki E; Kawabata Y; Kozawa J; Shimada A; Takahashi K; Tanaka S; Chujo D; Fukui T; Miura J; Yasuda K; Yasuda H; Kobayashi T; Hanafusa T;
    Diabetol Int; 2019 Jan; 10(1):58-66. PubMed ID: 30800564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulminant type 1 diabetes--an important subtype in East Asia.
    Imagawa A; Hanafusa T
    Diabetes Metab Res Rev; 2011 Nov; 27(8):959-64. PubMed ID: 22069293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research.
    Hosokawa Y; Hanafusa T; Imagawa A
    J Diabetes Investig; 2019 Sep; 10(5):1158-1164. PubMed ID: 31161717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review.
    Zhang X; Huang D; Lou D; Si X; Mao J
    BMC Endocr Disord; 2024 Sep; 24(1):172. PubMed ID: 39218880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case of new-onset fulminant type 1 diabetes mellitus accompanied by autoimmune thyroid disease after SARS-CoV-2 infection.
    Murakawa K; Aasi H; Sato K; Yoshioka S; Sho H; Inui R; Kosugi M; Hazama Y; Yasuda T
    Diabetol Int; 2024 Jul; 15(3):621-626. PubMed ID: 39101178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network Cluster Analysis of PPI and Phenotype Ontology for Type 1 Diabetes Mellitus.
    Zaeifi D; Azarnia M
    Iran J Biotechnol; 2024 Jan; 22(1):e3502. PubMed ID: 38827336
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.